Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: SofaSpud who wrote (13220)	12/17/2003 1:23:13 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Dimethaid provides corporate update TORONTO, Dec. 17 /CNW/ - Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX) has announced that it expects second-quarter sales of its lead product Pennsaid(R) to top $1.2 million US, representing a 70-percent increase over the previous quarter. The company also anticipates sales will continue growing throughout the remainder of the fiscal year. "We are extremely pleased with how well the marketplace has responded to Pennsaid," said Rebecca Keeler, president and CEO of Dimethaid Research Inc. Total revenue for the second quarter, ended November 30, 2003, will exceed $1.4 million US. The company expects to report its second quarter results in mid January. Business Development To continue expanding worldwide Pennsaid sales, Dimethaid is also focusing on new business partnerships in countries where the product has received final approval. Negotiations are now underway with marketing and sales organizations in Finland, Greece, Iceland and Portugal. Cash Management In November Dimethaid successfully completed a special warrant private placement, raising over $9.8 million US in net proceeds. The company is effectively managing its cash position in light of the recent Provalis arbitration award, and will continue to take appropriate steps to conserve cash as Pennsaid sales ramp up in Canada, Italy and the UK. About Dimethaid Research Inc. Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. The company develops and commercializes targeted therapeutic drugs designed to produce minimal side effects. Dimethaid's two technology platforms focus on immune system regulation and transcellular drug delivery. Products are aimed at expanding treatment options in oncology, immunology, rheumatology and the therapeutic management of chronic viral infections. For more information, please visit www.dimethaid.com.

To: SofaSpud who wrote (13220)	12/18/2003 12:46:38 PM
From: jef saunders	Read Replies (1) \| Respond to of 14101

SofaSpud, dmx pays their bills just as they have been the last years. they've been losing money for years now. why is this year any different ? they are operating at a deficit. they raised the almost $10 million from the warrents and they are living off of that. if they run out of money again before pennsaid sales causes them to be break even, they'll go out and get more money. they've got $400k sales a month now versus a year ago of less than $100k. hopefully by the time they need to raise cash again they will be in excess of $1M a month sales. that has to look good to some money guy out there. it's great news that the pennsaid sales are strong...it's the news that really matters. the number of months left for dmx to operate in the red is going down faster. so i disagree with you that we will be fortunate just to get our money out of the company. the product is very strong, whether or not you rate management as strong or weak. i'm a longterm holder too and expect dmx price over 100 someday. the "someday" though is more like 5-7 years instead of the 3-5 years i was hoping before. jefS

To: SofaSpud who wrote (13220)	12/18/2003 8:24:48 PM
From: axial	Respond to of 14101

Spud, despite the forecast for the upcoming year, people who are prepared to wait may see a return on their money. It all depends on what price they paid for their shares. People who are buying now will almost certainly see a return. Ownership is changing substantially as we speak, and new buyers have a different perspective on events, just as others like me did 3 years ago. None of the positive things said about Dimethaid have become untrue. Will Pennsaid sales trump the opposition in months to come? Will we see hidden forces break out into the open, or will RK continue to dance just beyond the reach of those who want to hang her? She can play this game a long time, and even among her greatest critics, there's major buying. What does that say about the future? Everything about DMX should work: a great idea for a new kind of pharma, innovative, safe products, and a CEO acknowledged to be clever and capable. But in 3 years, the only ones who've been mostly right about DMX have been the shorts and the bashers. Crazy, but true. FDA is an unknown, but there's always the possibility that it could happen in 2004. One day, you could wake up to a $10 or $20 stock. If you've been holding for years, what difference will one more year make? It's only money. Despite the ferocity of the debate, it's not worth living in a state of perpetual angst. Maybe jef has the right idea. In my case, I don't blame RK. I blame myself, and I've learned some lessons. Anyway, it'll be interesting to see what happens on DMX threads in the next year, as investors continue trying to solve the puzzle. Best of luck to all, and happy holidays. Jim